Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke
Background: The emerging role of stem cell technology and transplantation has helped scientists to study their potential role in neural repair and regeneration. The fate of stem cells is determined by their niche, consisting of surrounding cells and the secreted trophic growth factors. This interim...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2016-10-01
|
| Series: | Cerebrovascular Diseases Extra |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/446404 |
| _version_ | 1818989581680246784 |
|---|---|
| author | Ashu Bhasin M.V. Padma Srivastava Sujata Mohanty Sivasubramaniam Vivekanandhan Sakshi Sharma Senthil Kumaran Rohit Bhatia |
| author_facet | Ashu Bhasin M.V. Padma Srivastava Sujata Mohanty Sivasubramaniam Vivekanandhan Sakshi Sharma Senthil Kumaran Rohit Bhatia |
| author_sort | Ashu Bhasin |
| collection | DOAJ |
| description | Background: The emerging role of stem cell technology and transplantation has helped scientists to study their potential role in neural repair and regeneration. The fate of stem cells is determined by their niche, consisting of surrounding cells and the secreted trophic growth factors. This interim report evaluates the safety, feasibility and efficacy (if any) of bone marrow-derived mononuclear stem cells (BM-MNC) in chronic ischemic stroke by studying the release of serum vascular endothelial growth factor (VEGF) and brain-derived neurotrophic growth factor (BDNF). Methods: Twenty stroke patients and 20 age-matched healthy controls were recruited with the following inclusion criteria: 3 months to 1.5 years from the index event, Medical Research Council (MRC) grade of hand muscles of at least 2, Brunnstrom stage 2-5, conscious, and comprehendible. They were randomized to one group receiving autologous BM-MNC (mean 60-70 million) and to another group receiving saline infusion (placebo). All patients were administered a neuromotor rehabilitation regime for 8 weeks. Clinical assessments [Fugl Meyer scale (FM), modified Barthel index (mBI), MRC grade, Ashworth tone scale] were carried out and serum VEGF and BDNF levels were assessed at baseline and at 8 weeks. Results: No serious adverse events were observed during the study. There was no statistically significant clinical improvement between the groups (FM: 95% CI 15.2-5.35, p = 0.25; mBI: 95% CI 14.3-4.5, p = 0.31). VEGF and BDNF expression was found to be greater in group 1 compared to group 2 (VEGF: 442.1 vs. 400.3 pg/ml, p = 0.67; BDNF: 21.3 vs. 19.5 ng/ml) without any statistically significant difference. Conclusion: Autologous mononuclear stem cell infusion is safe and tolerable by chronic ischemic stroke patients. The released growth factors (VEGF and BDNF) in the microenvironment could be due to the paracrine hypothesis of stem cell niche and neurorehabilitation regime. |
| first_indexed | 2024-12-20T19:40:45Z |
| format | Article |
| id | doaj.art-feac55a2ae6f49dea281cdbae5f64bb7 |
| institution | Directory Open Access Journal |
| issn | 1664-5456 |
| language | English |
| last_indexed | 2024-12-20T19:40:45Z |
| publishDate | 2016-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Cerebrovascular Diseases Extra |
| spelling | doaj.art-feac55a2ae6f49dea281cdbae5f64bb72022-12-21T19:28:33ZengKarger PublishersCerebrovascular Diseases Extra1664-54562016-10-016310711910.1159/000446404446404Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic StrokeAshu BhasinM.V. Padma SrivastavaSujata MohantySivasubramaniam VivekanandhanSakshi SharmaSenthil KumaranRohit BhatiaBackground: The emerging role of stem cell technology and transplantation has helped scientists to study their potential role in neural repair and regeneration. The fate of stem cells is determined by their niche, consisting of surrounding cells and the secreted trophic growth factors. This interim report evaluates the safety, feasibility and efficacy (if any) of bone marrow-derived mononuclear stem cells (BM-MNC) in chronic ischemic stroke by studying the release of serum vascular endothelial growth factor (VEGF) and brain-derived neurotrophic growth factor (BDNF). Methods: Twenty stroke patients and 20 age-matched healthy controls were recruited with the following inclusion criteria: 3 months to 1.5 years from the index event, Medical Research Council (MRC) grade of hand muscles of at least 2, Brunnstrom stage 2-5, conscious, and comprehendible. They were randomized to one group receiving autologous BM-MNC (mean 60-70 million) and to another group receiving saline infusion (placebo). All patients were administered a neuromotor rehabilitation regime for 8 weeks. Clinical assessments [Fugl Meyer scale (FM), modified Barthel index (mBI), MRC grade, Ashworth tone scale] were carried out and serum VEGF and BDNF levels were assessed at baseline and at 8 weeks. Results: No serious adverse events were observed during the study. There was no statistically significant clinical improvement between the groups (FM: 95% CI 15.2-5.35, p = 0.25; mBI: 95% CI 14.3-4.5, p = 0.31). VEGF and BDNF expression was found to be greater in group 1 compared to group 2 (VEGF: 442.1 vs. 400.3 pg/ml, p = 0.67; BDNF: 21.3 vs. 19.5 ng/ml) without any statistically significant difference. Conclusion: Autologous mononuclear stem cell infusion is safe and tolerable by chronic ischemic stroke patients. The released growth factors (VEGF and BDNF) in the microenvironment could be due to the paracrine hypothesis of stem cell niche and neurorehabilitation regime.http://www.karger.com/Article/FullText/446404Chronic ischemic strokeAutologous mononuclear stem cell infusionIntravenous bone marrow-derived mononuclear stem cells |
| spellingShingle | Ashu Bhasin M.V. Padma Srivastava Sujata Mohanty Sivasubramaniam Vivekanandhan Sakshi Sharma Senthil Kumaran Rohit Bhatia Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke Cerebrovascular Diseases Extra Chronic ischemic stroke Autologous mononuclear stem cell infusion Intravenous bone marrow-derived mononuclear stem cells |
| title | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
| title_full | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
| title_fullStr | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
| title_full_unstemmed | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
| title_short | Paracrine Mechanisms of Intravenous Bone Marrow-Derived Mononuclear Stem Cells in Chronic Ischemic Stroke |
| title_sort | paracrine mechanisms of intravenous bone marrow derived mononuclear stem cells in chronic ischemic stroke |
| topic | Chronic ischemic stroke Autologous mononuclear stem cell infusion Intravenous bone marrow-derived mononuclear stem cells |
| url | http://www.karger.com/Article/FullText/446404 |
| work_keys_str_mv | AT ashubhasin paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT mvpadmasrivastava paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT sujatamohanty paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT sivasubramaniamvivekanandhan paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT sakshisharma paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT senthilkumaran paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke AT rohitbhatia paracrinemechanismsofintravenousbonemarrowderivedmononuclearstemcellsinchronicischemicstroke |